News
Targeted Therapy, Treatment Disparity Featured at Cancer Meeting
Leading cancer researchers from UC San Francisco presented talks about advances in targeted therapy, cancer genomics, eliminating treatment disparities and other cancer research topics at this year’s annual meeting of the American Association for Cancer Research (AACR) conference, which was held
Gene Therapy Is Halting Cancer. Can It Work Against Brain Tumors?
A type of gene therapy called CAR-T that has extended survival for thousands of patients with leukemia and other blood cancers is being adapted at UC San Francisco to treat people with glioblastoma, the most common and deadly adult brain tumor. This new more powerful version of CAR-T employs a novel
Advances in Targeted Therapy, Treatment Disparities Among Cancer Conference Talks
Advances in targeted therapy, cancer genomics and eliminating treatment disparities among the topics that will be presented by leading cancer researchers from UC San Francisco at this year’s annual meeting of the American Association for Cancer Research (AACR) conference, held April 5-10, in San
UCSF Scientists Build a Molecular ‘GPS’ to Guide Cell Therapies
The ideal therapy for a disease works exclusively at the site of the disease. But when it comes to the brain, which is wrapped in a protective barrier and contains thousands of different cell types, this ideal is very hard to achieve. Now, scientists at UC San Francisco have been awarded more than
Academic Spotlight: Juan Qin, PhD
Juan Qin, PhD, (pronounced “JOO-anh CHEEN”) grew up in Anhui Province, China in a small mountain village that was so remote that neighboring villages each spoke their own dialect. “We had very limited access to information, and people around me got cancer without receiving access to any treatment,”
Targeted Treatment of Rare Childhood Leukemia
Juvenile myelomonocytic leukemia (JMML) is a rare but aggressive childhood leukemia. While hematopoietic stem cell transplantation is curative for some patients, approximately half of all patients will still have their leukemia return following a transplant. Recent studies have identified that the